Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Gross Profit (2022 - 2025)

Arcutis Biotherapeutics has reported Gross Profit over the past 4 years, most recently at $113.8 million for Q4 2025.

  • Quarterly results put Gross Profit at $113.8 million for Q4 2025, up 82.24% from a year ago — trailing twelve months through Dec 2025 was $333.4 million (up 90.05% YoY), and the annual figure for FY2025 was $335.4 million, up 127.51%.
  • Gross Profit for Q4 2025 was $113.8 million at Arcutis Biotherapeutics, up from $90.5 million in the prior quarter.
  • Over the last five years, Gross Profit for ARQT hit a ceiling of $113.8 million in Q4 2025 and a floor of $456000.0 in Q3 2022.
  • Median Gross Profit over the past 4 years was $34.0 million (2023), compared with a mean of $39.9 million.
  • Biggest five-year swings in Gross Profit: soared 6219.74% in 2023 and later rose 18.79% in 2025.
  • Arcutis Biotherapeutics' Gross Profit stood at $2.5 million in 2022, then soared by 355.57% to $11.3 million in 2023, then surged by 453.68% to $62.5 million in 2024, then skyrocketed by 82.24% to $113.8 million in 2025.
  • The last three reported values for Gross Profit were $113.8 million (Q4 2025), $90.5 million (Q3 2025), and $74.0 million (Q2 2025) per Business Quant data.